We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Abzena | LSE:ABZA | London | Ordinary Share | GB00BN65QN46 | ORD GBP0.002 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 15.75 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMABZA
RNS Number : 0697K
Abzena PLC
04 July 2017
Abzena plc
Exercise of options
Cambridge, UK, 4 July 2017 - Abzena plc (AIM: ABZA, 'Abzena', the 'Company' or the 'Group') announces that on 4th July 2017, 35,333 new ordinary shares of GBP0.002 each in the Company ('Ordinary Shares') were issued and allotted following the exercise of share options. The new Ordinary Shares rank pari passu with the Company's existing issued Ordinary Shares and have been admitted to trading on AIM under the Company's block admission.
Total voting rights
Following the issue of 35,333 new Ordinary Shares pursuant to the option exercise set out above, the Company's issued share capital comprises 213,639,236 Ordinary Shares with voting rights. No Ordinary Shares are held in Treasury. The total number of voting rights in the Company is therefore 213,639,236. This figure of 213,639,236 Ordinary Shares may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.
-Ends-
Enquiries:
Abzena plc John Burt, Chief Executive Officer Julian Smith, Chief Financial Officer +44 1223 903498 Numis (Nominated Adviser and Broker) Clare Terlouw / James Black / Paul Gillam +44 20 7260 1000 N+1 Singer (Joint Broker) Aubrey Powell / Liz Yong +44 20 7496 3069 Instinctif Partners +44 20 7457 2020 Melanie Toyne Sewell / Alex abzena@instinctif.com Shaw
Notes to Editors
About Abzena
Abzena (AIM: ABZA) provides proprietary technologies and complementary services to enable the development and manufacture of biopharmaceutical products.
The term 'Abzena inside' is used by Abzena to describe products that have been created using its proprietary technologies and are being developed by its partners, and include Composite Human Antibodies(TM) and ThioBridge(TM) Antibody Drug Conjugates (ADCs). Abzena has the potential to earn future licence fees, milestone payments and/or royalties on 'Abzena inside' products.
Abzena offers the following services and technologies across its principal sites in Cambridge (UK), San Diego, California (USA) and Bristol, Pennsylvania (USA):
-- Immunology research studies, including immunogenicity assessment of candidate biopharmaceutical products;
-- Protein engineering to create humanized antibodies and deimmunised therapeutic proteins; -- Cell line development for the manufacture of recombinant proteins and antibodies;
-- Contract process development and GMP manufacture of biopharmaceuticals, including monoclonal antibodies and recombinant proteins for preclinical and clinical studies;
-- Contract synthetic chemistry and bioconjugation research services, focused on antibody-drug conjugates (ADCs);
-- Proprietary site-specific conjugation technologies and novel payloads for ADC development; and
-- GMP manufacturer of ADC linkers, payloads & combined linker-payloads.
For more information, please see www.abzena.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCEAEXLEADXEFF
(END) Dow Jones Newswires
July 04, 2017 06:24 ET (10:24 GMT)
1 Year Abzena Chart |
1 Month Abzena Chart |
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions